Amalgamated Financial’s Syros Pharmaceuticals, Inc. Common Stock SYRS Stock Holding History

Amalgamated Financial’s Portfolio SYRS Stock Details SYRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	$10K	Buy	+811	New	+$14.5K	﹤0.01%	2903

Other funds holding SYRS

BCLSI

Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

ABG

Ally Bridge Group New York $113M AUM 245.92% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

Amalgamated Financial's SYRS Position: Q1 2022 in Review

Amalgamated Financial opened a new position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) in Q1 2022: 811 shares worth $10K. The stake represents ﹤0.01% of the portfolio and ranks #2903 among its holdings.

94 funds tracked by Wall St. Rank hold SYRS as of Q1 2022.

Amalgamated Financial held 811 shares of Syros Pharmaceuticals, Inc. Common Stock worth $10K as of Q1 2022.
Syros Pharmaceuticals, Inc. Common Stock was a new Amalgamated Financial position in Q1 2022.
Syros Pharmaceuticals, Inc. Common Stock made up ﹤0.01% of Amalgamated Financial's portfolio in Q1 2022, its #2903 holding.
94 funds tracked by Wall St. Rank held Syros Pharmaceuticals, Inc. Common Stock as of Q1 2022.

Based on Amalgamated Financial's 13F filing for Q1 2022, filed 16 May 2022.